Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.59 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.59 |
| ▸ | SQLE | Q14534 | 7/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6905662 | 1.00 | KMT2A (0.67) | KMT2AMAPTALDH1A1MEN1CYP3A4 | |
| SCHEMBL6905707 | 0.96 | ALDH1A1 (0.61) | KMT2AMAPTALDH1A1MEN1CYP3A4 | |
| SCHEMBL6905709 | 0.96 | ALDH1A1 (0.61) | KMT2AMAPTALDH1A1MEN1CYP3A4 | |
| SCHEMBL109310 | 0.82 | KMT2A (0.73) | KMT2AMAPTALDH1A1MEN1CYP3A4 | |
| SCHEMBL29059665 | 0.82 | KMT2A (0.73) | KMT2AMAPTALDH1A1MEN1CYP3A4 | |
| SCHEMBL2896117 | 0.82 | KMT2A (0.73) | KMT2AMAPTALDH1A1MEN1CYP3A4 | |
| SCHEMBL2841894 | 0.82 | KMT2A (0.73) | KMT2AMAPTALDH1A1MEN1CYP3A4 | |
| SCHEMBL23802597 | 0.81 | KMT2A (1.00) | KMT2AMAPTALDH1A1MEN1CYP3A4 | |
| SCHEMBL8013144 | 0.81 | KMT2A (1.00) | KMT2AMAPTALDH1A1MEN1CYP3A4 | |
| Squalene SCHEMBL8819997 | 0.81 | KMT2A (1.00) | KMT2AMAPTALDH1A1MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6703527-B2 | REACTING ALLYL ALCOHOL COMPOUND SUCH AS 2E,6E-3,7,11-TRIMETHYL-2,6,10-DODECATRIEN-1-OL WITH HYDRIDE ACCEPTOR SUCH AS 2-NITROBENZALDEHYDE IN THE PRESENCE OF AN ALUMINIUM ALKOXIDE AS AN OPPENAUER OXIDATION CATALYST | NIKKEN CHEMICALS CO., LTD. (JP) | 2004-03-09 | — | — | US | disclosed |
| US-20020198411-A1 | Method for oxidation of allyl alcohol | NIKKEN CHEMICALS CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198411-A1 | Method for oxidation of allyl alcohol | ADH1A, ADH1C, ADH5 | KMT2A 750/4885MAPT 2027/4885ALDH1A1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.